Dr. Ross Okimoto is a medical oncologist specializing in the care of adult patients with soft tissue and bone sarcomas. He works with a team of surgeons, radiation oncologists and pathologists to provide the best possible outcomes for his patients.
Okimoto attended Creighton University School of Medicine. He completed his internal medicine residency training at Tufts Medical Center in Boston and his medical oncology fellowship at UCSF.
A physician-scientist, Okimoto conducts research in addition to providing clinical care. The overall goal of his laboratory-based investigations is to help improve outcomes for cancer patients. His current research work focuses on understanding the molecular mechanisms that promote tumor cell metastasis.
Most recent publications from a total of 23
Okimoto RA, Bivona TG. Metastasis: From Head to Tail. Cell Cycle. 2017 Jan 05; 0. View in PubMed
Okimoto RA, Breitenbuecher F, Olivas VR, Wu W, Gini B, Hofree M, Asthana S, Hrustanovic G, Flanagan J, Tulpule A, Blakely CM, Haringsma HJ, Simmons AD, Gowen K, Suh J, Miller VA, Ali S, Schuler M, Bivona TG. Inactivation of Capicua drives cancer metastasis. Nat Genet. 2016 Nov 21. View in PubMed
Okimoto RA, Lin L, Olivas V, Chan E, Markegard E, Rymar A, Neel D, Chen X, Hemmati G, Bollag G, Bivona TG. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Proc Natl Acad Sci U S A. 2016 Nov 9. View in PubMed
Premasekharan G, Gilbert E, Okimoto RA, Hamirani A, Lindquist KJ, Ngo VT, Roy R, Hough J, Edwards M, Paz R, Foye A, Sood R, Copren KA, Gubens M, Small EJ, Bivona TG, Collisson EA, Friedlander TW, Paris PL. An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. Cancer Lett. 2016 Sep 28; 380(1):144-52. View in PubMed
Okimoto RA, Bivona TG. Tracking Down Response and Resistance to TRK Inhibitors. Cancer Discov. 2016 Jan; 6(1):14-6. View in PubMed
Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015 Sep; 21(9):1038-47. View in PubMed
Okimoto RA, Bivona TG. AXL as a therapeutic target in NSCLC. Lung Cancer: Targets and Therapy. 2015; 6:27-34. View in PubMed
Okimoto RA, Perry A, Rubenstein JL. 77-year-old woman with a dural-based mass. Marginal zone B-cell lymphoma (MZBCL). Brain Pathol. 2015 Jan; 25(1):111-2. View in PubMed
Okimoto RA, Bivona TG. Recent advances in personalized lung cancer medicine. Per Med. 2014; 11(3):309-321. View in PubMed
Okimoto RA, Van Etten RA. Navigating the road toward optimal initial therapy for chronic myeloid leukemia. Curr Opin Hematol. 2011 Mar; 18(2):89-97. View in PubMed
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.